A&I Financial Services LLC Invests $402,000 in Organon & Co. (NYSE:OGN)

A&I Financial Services LLC purchased a new stake in shares of Organon & Co. (NYSE:OGN) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 26,924 shares of the company’s stock, valued at approximately $402,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Sippican Capital Advisors increased its holdings in Organon & Co. by 4.3% during the 3rd quarter. Sippican Capital Advisors now owns 15,230 shares of the company’s stock valued at $291,000 after purchasing an additional 627 shares in the last quarter. Commerce Bank increased its holdings in Organon & Co. by 5.5% during the 3rd quarter. Commerce Bank now owns 12,168 shares of the company’s stock valued at $233,000 after purchasing an additional 637 shares in the last quarter. MassMutual Private Wealth & Trust FSB increased its holdings in Organon & Co. by 32.4% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock valued at $41,000 after purchasing an additional 672 shares in the last quarter. Graypoint LLC increased its holdings in Organon & Co. by 6.2% during the 3rd quarter. Graypoint LLC now owns 14,555 shares of the company’s stock valued at $278,000 after purchasing an additional 853 shares in the last quarter. Finally, CIBC Asset Management Inc increased its holdings in Organon & Co. by 4.9% during the 4th quarter. CIBC Asset Management Inc now owns 25,523 shares of the company’s stock valued at $381,000 after purchasing an additional 1,184 shares in the last quarter. 77.43% of the stock is owned by institutional investors and hedge funds.

Organon & Co. Stock Performance

OGN stock opened at $15.03 on Friday. The business’s 50-day moving average price is $15.43 and its two-hundred day moving average price is $17.17. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. The firm has a market cap of $3.87 billion, a PE ratio of 4.51, a P/E/G ratio of 0.90 and a beta of 0.76. Organon & Co. has a 1-year low of $13.87 and a 1-year high of $23.10.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). The firm had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. As a group, research analysts forecast that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 13th. Stockholders of record on Monday, February 24th will be issued a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.45%. The ex-dividend date of this dividend is Monday, February 24th. Organon & Co.’s dividend payout ratio is presently 33.63%.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on OGN. Barclays dropped their price target on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a report on Friday, February 14th. TD Cowen raised Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. Finally, Morgan Stanley lowered their target price on Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a research note on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $20.80.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.